Galectin-3 in heart failure van der Velde, Allart Rogier IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2017 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): van der Velde, A. R. (2017). Galectin-3 in heart failure: From biomarker to target for therapy [Groningen]: Rijksuniversiteit Groningen Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 17-03-2017
Galectin-3 in heart failure From biomarker to target for therapy Rogier van der Velde
Van der Velde, Allart Rogier Galectin-3 in heart failure: from biomarker to target for therapy ISBN: 978-94-6169-998-5 ISBN: 978-90-77595-41-1 (PDF) Copyright 2016 A.R. van der Velde All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the written permission of the author. Cover design, layout and printing by Optima Grafische Communicatie
Galectin-3 in heart failure From biomarker to target for therapy Proefschrift ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen op gezag van de rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op woensdag 11 januari 2017 om 16.15 uur door Allart Rogier van der Velde geboren op 5 augustus 1984 te Zwolle
Promotores Prof. dr. R.A. de Boer Prof. dr. W.H. van Gilst Copromotor Dr. H.H.W. Silljé Beoordelingscommissie Prof. dr. A.A. Voors Prof. dr. H.P. Brunner- La Rocca Prof. dr. H.A. Schols
Paranimfen Drs. G.H. van Dijk Drs. W.C.F.W. Meijers
Table of contents Chapter 1 Introduction 9 PART 1: Galectin-3 as a prognostic factor Chapter 2 Biomarkers for Risk Prediction in Acute Decompensated Heart Failure Current Heart Failure Reports (2014); 11:246-259 Chapter 3 Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure: Data From CORONA and COACH Circulation: Heart Failure (2013); 6:219-226 Chapter 4 Serial Galectin-3 and Future Cardiovascular Disease in the General Population Heart (2016); 102:1134-1141 Chapter 5 Galectin-3 and Post-Myocardial Infarction Cardiac Remodeling European Journal of Pharmacology (2015); 763: 115-121 Chapter 6 Galectin-3 and sst2 in Prediction of Left Ventricular Ejection Fraction after Myocardial Infarction Clinica Chimica Acta (2016); 452: 50-57 27 57 81 115 135 PART 2: The role of galectin-3 in cardiac disease - biology of galectin-3 Chapter 7 Determinants of Temporal Changes in Galectin-3 Level in the General Population: Data of PREVEND International Journal of Cardiology (2016); 222: 385-390 Chapter 8 Galectin-3 and ABO Blood Group: Effects on Plasma Level, Prognosis and Binding Properties Manuscript in preparation 159 179 PART 3: Galectin-3 as a modifiable factor in heart failure Chapter 9 Galectin-3: a Modifiable Risk Factor in Heart Failure 203 Cardiovascular Drugs and Therapy (2014); 28: 237 246 Chapter 10 Pectins from Various Sources Inhibit Galectin-3-related Cardiac 221 Fibrosis Submitted Chapter 11 General discussion 245 Appendices Summary in Dutch - Nederlandse samenvatting 267 Acknowledgements - Dankwoord 281 Bibliography 289 Curriculum Vitae 293